期刊
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA
卷 28, 期 4, 页码 631-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.soc.2019.06.014
关键词
Distal cholangiocarcinoma; Extrahepatic cholangiocarcinoma; Adjuvant therapy; Risk factors; Surgery
Distal cholangiocarcinoma is a rare malignancy with a dismal prognosis. Because of its location and aggressive nature, patients often present with locally advanced or metastatic disease, and effective treatment options are limited. For patients with resectable disease, surgery is the only chance for cure, but achieving an R0 resection is paramount. Optimal adjuvant therapy in resectable disease remains under investigation. Randomized controlled trials investigating neoadjuvant therapy and its impact on resectability and long-term outcomes are needed to continue to improve the outcomes of patients with distal cholangiocarcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据